Compare MLM & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLM | RMD |
|---|---|---|
| Founded | 1993 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6B | 28.4B |
| IPO Year | 1996 | 1996 |
| Metric | MLM | RMD |
|---|---|---|
| Price | $548.78 | $225.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 10 |
| Target Price | ★ $689.36 | $292.56 |
| AVG Volume (30 Days) | 566.0K | ★ 1.4M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | 0.54% | ★ 1.13% |
| EPS Growth | N/A | ★ 9.67 |
| EPS | ★ 29.27 | 10.43 |
| Revenue | ★ $6,150,000,000.00 | $2,957,013,000.00 |
| Revenue This Year | $13.76 | $10.60 |
| Revenue Next Year | $7.98 | $7.41 |
| P/E Ratio | ★ $18.61 | $29.10 |
| Revenue Growth | N/A | ★ 13.44 |
| 52 Week Low | $523.48 | $180.27 |
| 52 Week High | $710.97 | $293.81 |
| Indicator | MLM | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 63.73 |
| Support Level | $524.43 | $218.39 |
| Resistance Level | $633.80 | $233.75 |
| Average True Range (ATR) | 15.63 | 6.92 |
| MACD | 0.88 | 1.37 |
| Stochastic Oscillator | 42.25 | 95.60 |
Martin Marietta Materials is one of the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). In 2024, Martin Marietta sold 191 million tons of aggregates. Martin Marietta's most important markets include Texas, North Carolina, Colorado, California, and Georgia, accounting for most of its sales. The company also uses its aggregates in its asphalt and ready-mixed concrete businesses. Martin's magnesia specialties business produces magnesia-based chemical products and dolomitic lime.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.